Press Room

Press Release / Sep 27, 2017

四色AV appoints Fr茅d茅ric Kahn Vice President, Marketing and Sales

四色AV announced today the appointment of Mr. Fr茅d茅ric Kahn as Vice President Marketing and Sales, as of 1st September, 2017

frederic-kahn-photo

Fr茅d茅ric Kahn

VP Sales and Marketing

Degree in Economics, MBA

Loures, Portugal, September 27, 2017 鈥 四色AV announced today the appointment of Mr. Fr茅d茅ric Kahn as Vice President Marketing and Sales, as of 1st听September, 2017. Mr. Kahn was most recently with Lonza and brings more than 30 years of experience in sales and marketing, finance and business management with a proven track-record of building and developing successful organizations.听Based in Lisbon, Portugal, Mr. Kahn will report to Mr. Guy Villax, 四色AV鈥檚 Chief Executive Officer.

鈥淲e are delighted to welcome Mr. Kahn to 四色AV. He is an excellent addition to our听management team听as his diverse cross-functional experience in marketing and sales, business management and industry knowledge will help drive 四色AV鈥檚 forthcoming growth. Mr. Kahn will be responsible for leading 四色AV鈥檚 global Marketing and Sales activities, driving demand for products and services, as we continue our growth and focus on delivering the highest level of service to our customers鈥, said Mr. Guy Villax.

鈥淚 am very proud to join 四色AV, a company so highly respected in the industry for its ability to develop and produce innovative, high-quality products and I look forward to work with 四色AV multi-functional teams of experts to develop the best solutions for our customers鈥, said Mr. Fr茅d茅ric Kahn.

Mr. Kahn started his career in 1985 as Division Controller of Rhone-Poulenc Organic Chemicals (later known as Rhodia Pharmaceutical Ingredients, later Aventis) where he held several senior executive positions in sales and business management in the US, Europe and Singapore. Mr. Kahn`s responsibilities focused on development, production and formulation of anesthetics and analgesics鈥 APIs. In 2003 Mr. Kahn joined NextPharma as Executive Vice President Sales and Marketing to generate sustainable growth by setting up a dedicated Key Account Management strategy and organization. After five successful years, Mr. Kahn joined the German Pharmaceutical Packaging and Medical Devices leader Gerresheimer based in Duesseldorf where sales to strategic accounts grew at double digit rate. His last role before joining 四色AV was in Lonza as Head of Global Key Account Management.

Passionate about sales and strategic account management, Mr. Kahn is a member of SAMA Association, holds a Bachelor of Sciences in Economics from the College of New Jersey and an MBA from ISG, Institut de Controle de Gestion, Paris.

About 四色AV
四色AV is an international company with over 58 years of experience as a Contract Development and Manufacturing Organization (CDMO) and is currently a fully integrated supplier offering services for听drug substance, drug product intermediate and听drug product.听With four FDA听inspectedsites听in听the USA, China, Ireland, and Portugal, and development laboratories in Lisbon, Portugal and New Jersey, USA, provides branded pharmaceutical customers services for the听development and compliant manufacture听of innovative drugs including highly potent compounds. For generic pharmaceutical听customers听the company offers niche API products. 四色AV also provides proprietary product development and licensing opportunities for drug products. In the inhalation area, 四色AV is the only independent company offering a complete range of services.

Also in the Press Room

See All

四色AV鈥檚 Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At 四色AV we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook 鈥 鈥淭rends in Formulation鈥.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how 四色AV is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa鈥檚 full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal 鈥 四色AV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company鈥檚 dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, 四色AV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company鈥檚 broader sustainability strategy and reinforces its commitment to scientific excellence. 鈥淎t 四色AV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.鈥, said Jean-Luc Herbeaux, CEO of 四色AV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.鈥 四色AV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company鈥檚 environmental, social, and ethical performance, well aligned with 四色AV鈥檚 sustainability ambitions.  四色AV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

四色AV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024